BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19334634)

  • 1. [Nonlinear nature of the antiarrhythmic effects of lidocain].
    Moskalenko AV
    Biofizika; 2009; 54(1):62-7. PubMed ID: 19334634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiarrhythmic properties of afobazole and other 2-mercaptobensimidazole derivatives].
    Turilova AI; Mozhaeva TIa
    Eksp Klin Farmakol; 2010 May; 73(5):8-11. PubMed ID: 20597362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers.
    Ito I; Hayashi Y; Kawai Y; Iwasaki M; Takada K; Kamibayashi T; Yamatodani A; Mashimo T
    Anesth Analg; 2006 Sep; 103(3):545-50. PubMed ID: 16931659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative characteristic of sodium blocking properties of anti-arrhythmia agents on isolated rats cardiomyocytes].
    Khankoeva AI; Dukhanin AS; Galenko-Iaroshevskií PA
    Biull Eksp Biol Med; 1997 Jun; 123(6):666-8. PubMed ID: 9280522
    [No Abstract]   [Full Text] [Related]  

  • 5. The persistent sodium current blocker riluzole is antiarrhythmic and anti-ischaemic in a pig model of acute myocardial infarction.
    Weiss SM; Saint DA
    PLoS One; 2010 Nov; 5(11):e14103. PubMed ID: 21124787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia.
    Hashimoto K; Satoh H; Shibuya T; Imai S
    J Pharmacol Exp Ther; 1982 Dec; 223(3):801-10. PubMed ID: 7143241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models.
    Takahara A; Hirasawa A; Dohmoto H; Shoji M; Yoshimoto R; Sugiyama A; Hashimoto K
    Jpn J Pharmacol; 2001 Sep; 87(1):21-6. PubMed ID: 11676194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction.
    Wood DM; Dargan PI; Hoffman RS
    Clin Toxicol (Phila); 2009 Jan; 47(1):14-23. PubMed ID: 18815938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-arrhythmia properties of the novel combined preparation based on sufan and possible mechanism of their realization].
    Khankoeva AI; Dukhanin AS; Leonidov NB; Galenko-Iaroshevskiĭ PA; Galygo DS
    Biull Eksp Biol Med; 1998 Jan; 125(1):59-62. PubMed ID: 9532370
    [No Abstract]   [Full Text] [Related]  

  • 10. [The antiarrhythmic action of piracetam].
    Samvelian VM; Malakian MG; Badzhinian SA
    Farmakol Toksikol; 1990; 53(6):22-3. PubMed ID: 2081561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cutaneous analgesic effect of class I antiarrhythmic drugs.
    Tzeng JI; Cheng KI; Huang KL; Chen YW; Chu KS; Chu CC; Wang JJ
    Anesth Analg; 2007 Apr; 104(4):955-8. PubMed ID: 17377113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of fluorine on heart arrhythmias in rats].
    Karpova MN
    Biull Eksp Biol Med; 1989 Mar; 107(3):281-3. PubMed ID: 2540850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ionic mechanisms in heart muscle in relation to the genesis and the pharmacological control of cardiac arrhythmias.
    Hauswirth O; Singh BN
    Pharmacol Rev; 1978 Mar; 30(1):5-63. PubMed ID: 377312
    [No Abstract]   [Full Text] [Related]  

  • 14. Model systems for the discovery and development of antiarrhythmic drugs.
    Nattel S; Duker G; Carlsson L
    Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias.
    Ogawa R; Kishi R; Mihara K; Takahashi H; Takagi A; Matsumoto N; Masuhara K; Nakazawa K; Miyake F; Kobayashi S; Echizen H
    J Clin Pharmacol; 2006 Jan; 46(1):59-68. PubMed ID: 16397285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonistic effects of tetrodotoxin on aconitine-induced cardiac toxicity.
    Ono T; Hayashida M; Tezuka A; Hayakawa H; Ohno Y
    J Nippon Med Sch; 2013; 80(5):350-61. PubMed ID: 24189353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry.
    Comtois P; Kneller J; Nattel S
    Europace; 2005 Sep; 7 Suppl 2():10-20. PubMed ID: 16102499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studying the mechanism of antiarrhythmic action of a tertiary derivative of lidocaine].
    Blinov DS; Kostin IaV; Skachilova SIa
    Eksp Klin Farmakol; 2004; 67(3):18-20. PubMed ID: 15341061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiarrhythmic effect of the antiopioid peptide nociceptin and its effect on fast Na+-channels in cardiomyocytes].
    Lishmanov IuB; Krylatov AV; Maslov LN
    Biull Eksp Biol Med; 1998 Dec; 126(12):655-7. PubMed ID: 9934512
    [No Abstract]   [Full Text] [Related]  

  • 20. From pulsus to pulseless: the saga of cardiac alternans.
    Weiss JN; Karma A; Shiferaw Y; Chen PS; Garfinkel A; Qu Z
    Circ Res; 2006 May; 98(10):1244-53. PubMed ID: 16728670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.